Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05601180
Other study ID # RESPIRE DZ
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 27, 2022
Est. completion date January 15, 2024

Study information

Verified date March 2024
Source Beker Laboratories
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study Product) Evaluating the Efficacy of Respicure® 0.38% /0.38% (Resveratrol / Quercetin) Phytotherapy Product From BEKER Laboratories as an add-on Treatment in the Management of Respiratory Conditions Including Asthma (Partially Controlled),COPD (Stage A, B, C and D) and long COVID in Algerian Adult Patients .


Description:

This is an interventional, prospective, national, multicenteric, randomized, open-label, controlled clinical study comparing two arms: Control arm taking the standard of care Versus Intervention arm (standard of care + Respicure®). A total of 480 patients (160 in each group of pathology i.e Asthme, COPD and long COVID, distributed through 8 centers resulting in 20 patients/center for each group of pathology). The administration of the study product is by randomaisation.The data will be collected during 5 visits for the two arms as following: - Visit V1 on D0: inclusion, signature of informed consent and implementation of the RESPIRE DZ protocol with delivery to patients of a one-month supply of Respicure® for the intervention arm, - Intermediary visit on D15: face-to-face and/or by telephone to assess safety after the use of Respicure® for the intervention arm. - Visit V2 on D30: follow-up visit with delivery to patients of a one-month supply of Respicure® for the intervention arm, - Visit V3 on D60: follow-up visit with delivery to patients of a one-month supply of Respicure® for the intervention arm, - Visit V4 at D90:follow-up visit at the end of the use of the study product, - Visit V5 at D180: follow-up and end-of-study visit.


Recruitment information / eligibility

Status Completed
Enrollment 402
Est. completion date January 15, 2024
Est. primary completion date January 15, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility - Inclusion Criteria for Asthma patients: 1. Male, female, aged =19. 2. Being able to provide written informed consent before the study. 3. Patient with partially controlled asthma: Assessment of asthma control over the month preceding the use of Respicure ® by a symptomatic assessment (Tick one or two symptoms): 3. 1 Daytime symptoms more than twice a week, 3. 2 One or more nocturnal awakenings, 3. 3 Need for rescue medication more than twice a week, 3. 4 One or more activity limitations 4. Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc… - Inclusion Criteria for COPD patients: 1. Male, female, =40 years old 2. Being able to provide written informed consent before the study. 3. Patient with COPD stage A, B, C or D in stable condition with no exacerbations in the past 4 weeks. 4. Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc… - Inclusion Criteria for long covid patients: 1. Male, female, aged =19. 2. Being able to provide written informed consent before the study. 3. Patients followed for respiratory symptoms linked to long Covid (symptoms for more than 12 weeks). Exclusion Criteria : 1. Patient with severe asthma (for asthma groupe only) 2. Prior use of Respicure®. 3. Concomitant use with the following products: cytochrome P450 3A4 substrate drugs (e.g. statin, antifungals and fexofenadine), antibiotics (quinolones), immunosuppressants (cyclosporine) and glycoprotein P substrate drugs, e.g. antifungal and antiarrhythmic . 4. Hypersensitivity to any of the ingredients. 5. Hypersensitivity to peanuts. 6. Concomitant intake of a product containing one or both of the active ingredients (resveratrol/quercetine). 7. Pregnancy/ lactation. 8. People who need to undergo surgery. 9. Participation in another clinical study within the previous 30 days. 10. Patient with asthma-COPD overlap syndrome or any other respiratory disease such as pneumonia, tuberculosis, pulmonary embolism, etc. 11. Hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis or uterine fibroids. 12. Patients requiring admission to intensive care and/or requiring respiratory assistance. 13. Patients requiring anticoagulant treatment at curative doses.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Respicure®
Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.
Standard of care
standard treatment is prescribed by the treating physician.

Locations

Country Name City State
Algeria CHU Beni Messous/Pneumologie A Algiers
Algeria CHU Beni Messous/Pneumologie B Algiers
Algeria CHU Annaba/Pneumo-phtisiologie Annaba
Algeria EPH Batna/Pneumo-phtisiologie Batna
Algeria CHU Constantine/Pneumo-phtisiologie Constantine
Algeria EPH Laghouat/Pneumo-phtisiologie Laghouat
Algeria CHU Oran/Pneumo-phtisiologie B Oran
Algeria CHU Sidi Bel Abbes/Pneumo-phtisiologie Sidi Bel Abbès

Sponsors (1)

Lead Sponsor Collaborator
Beker Laboratories

Country where clinical trial is conducted

Algeria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of asthma symptoms in partially controlled patients . The assessment of asthma management will be based on:
1. Improvement in symptoms measured at baseline and during the follow-up period and results will be compared to those of the control group to determine asthma control using the following criteria:
Daytime symptoms at most twice a week,
No nocturnal awakenings,
Need for rescue medication at most twice a week,
No limitation of activities.
Change from Baseline at 3 months
Primary Change of COPD symptoms in patients with stage A, B, C or D. The assessment of reduction in symptoms will be be compared to those of the control group and will be based on reducing CAT scoring "COPD assessment test" to be less than 10. Change from Baseline at 3 months
Primary Change of COPD symptoms in patients with stage A, B, C or D. The assessment of reduction in symptoms will be based on reducing mMRC scoring "modified Medical Research Council" where 0 being the best and 4 being the worst. Change from Baseline at 3 months.
Primary Change of respiratory symptoms related to long COVID. The assessment of the respiratory symptoms linked to long COVID will be based on the reduction in dyspnea and cough by measuring m mMRC scoring "modified Medical Research Council" where 0 being the best and 4 being the worst. Change from Baseline at 3 months
Primary Change of respiratory symptoms related to long COVID. The assessment of the respiratory symptoms linked to long COVID will be based on:
- Improvement of Blood oxygen saturation.
Change from Baseline at 3 months
Secondary Tolerance Tolerance to Respicure®: assessment of the occurrence of serious/non-serious adverse events during the study period. 3 months
Secondary Morbidity for Asthma patients Minimisation or absence of hospitalisation and Reduction of number of exacerbations 3 months
Secondary Change of CAT scoring for Asthma patients Improvement of CAT scoring (Asthma control test) more than 20. Change from Baseline at 3 months
Secondary Change of Respiratory function for Asthma patients Evaluation of respiratory function by spirometry to detect Variation of PEF (Peak expiratory flow) compared to baseline (in %) Change from Baseline at 3 months
Secondary Change of Respiratory function for Asthma patients Evaluation of respiratory function by spirometry to detect:
Improved FEV1/FVC ratio (Forced expiratory volume in one second/ Forced vital capacity) compared to baseline (in %)
Change from Baseline at 3 months
Secondary Change of Respiratory function for Asthma patients Evaluation of respiratory function by spirometry to detect a decreased FEV1 (Forced expiratory volume in one second) variability compared to baseline (in %) Change from Baseline at 3 months
Secondary Morbidity & Exacerbations for COPD patients Minimisation or absence of hospitalisation and The prevention of future exacerbations "time to onset of the 1st exacerbation in six (06) months", 6 months
Secondary Exacerbations for COPD patients The prevention of future exacerbations "time to onset of the 1st exacerbation in six (06) months", 6 months.
Secondary Change of Respiratory function for COPD patients Evaluation of respiratory function by spirometry to detect variation of PEF (Peak expiratory flow) compared to baseline (in %) Change from Baseline at 3 months
Secondary Change of Respiratory function for COPD patients Evaluation of respiratory function by spirometry to detect variation of FEV (Forced expiratory volume) compared to baseline (in %) Change from Baseline at 3 months
Secondary Morbidity for long COVID patients Minimisation or absence of hospitalisation 6 months.
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device